Final CMS Aducanumab Decision Limits Coverage to Clinical Trials

In a final decision on the funding of the controversial Alzheimer's drug aducanumab, federal officials largely stuck to their draft plan to limit Medicare payment to patients enrolled in clinical trials.
News Alerts